Touch Surgery Enterprise

Bottom line

Touch Surgery Enterprise is a dual-mode platform: a free mobile surgical simulator available to any clinician worldwide, paired with a quote-based enterprise tier that adds AI-driven video capture and analytics for institutional programs. The free app is the clearest value proposition here. It offers procedure-specific cognitive walkthroughs across dozens of surgical specialties, from orthopedics to neurosurgery, with no subscription required. The enterprise tier, by contrast, remains opaque in both pricing and deployment specifics.

This tool is best suited for surgical residents, medical students, and early-career surgeons seeking low-friction skills practice outside the OR. The enterprise tier may appeal to program directors at academic medical centers or large surgical practices looking to implement video-based quality improvement workflows, but the evidence base is thin and the ROI math unclear. Medtronic's backing provides vendor stability, but the lack of published outcomes data, absent clinician testimonials, and single tangentially related PubMed citation mean this is a cautious recommendation for enterprise buyers.

Price band: USD 0 for the mobile app. Enterprise tier requires a custom quote, with no public pricing benchmarks available. For individual clinicians, this is a no-risk download. For institutions, expect multi-month vendor negotiations and unclear total cost of ownership.

Why we picked it

Touch Surgery Enterprise earned a silo pick in the AI Surgical Tools category as the best free mobile simulator because it delivers institutional-grade procedural training content with zero financial barrier. Most competing surgical simulation platforms, including Osso VR, FundamentalVR, and PrecisionOS, operate on per-seat licensing models that price out individual learners and smaller residency programs. Touch Surgery's free tier democratizes access to high-fidelity cognitive rehearsal for procedures ranging from total knee arthroplasty to anterior cervical discectomy.

The app's Medtronic provenance matters. This is not a startup gamble. Medtronic acquired the original Touch Surgery platform in 2020 and has maintained active development. The mobile simulator uses a validated cognitive task simulation framework, meaning it walks learners through decision trees, anatomical landmarks, and step sequencing rather than attempting full haptic VR. For many surgical trainees, this cognitive rehearsal mode is more accessible than VR headset-dependent platforms, which require dedicated hardware, IT setup, and physical space.

The enterprise tier's video analytics component is less differentiated. Tools like Theator, ExplORer Surgical, and GE Healthcare's procedural analytics modules offer similar AI-tagged intraoperative video review. What sets Touch Surgery apart is the bundled model: free individual training plus optional institutional video layer. If your surgical program already uses the free app widely, the enterprise upsell becomes a natural extension rather than a standalone procurement. That continuity is rare in this market.

Still, the evidence gap is real. The single PubMed citation we found discusses barriers to video management in surgery generally but does not evaluate Touch Surgery's platform specifically. No prospective trials, no comparative effectiveness studies, no published institutional case reports. The free app's value is self-evident through direct use. The enterprise tier's value remains hypothetical.

What it does well

The mobile app excels at procedural cognitive rehearsal. It covers over 200 surgical procedures across 15 specialties, with step-by-step interactive modules that quiz learners on decision points, anatomical identification, and complication management. The interface is polished, the content is regularly updated, and the delivery is mobile-first, meaning a resident can practice a laparoscopic cholecystectomy walkthrough on a tablet during downtime without needing OR access or faculty supervision. For early learners building mental models of operative flow, this is high-yield preparation.

Medtronic's institutional credibility lends weight. This is not a venture-backed startup that might vanish after a Series A fails. Medtronic Digital Surgery is a division of a USD 30 billion medical device multinational with deep relationships across academic medical centers, community hospitals, and surgical specialty societies. The company has the resources to sustain long-term platform development and the regulatory expertise to navigate FDA pathways if device-linked features emerge. For risk-averse IT departments and procurement teams, that stability reduces vendor-failure risk.

The enterprise tier, when deployed, offers AI-tagged video review with automatic identification of procedural phases, instrument usage, and anatomical structures. Surgical program directors can theoretically track resident case logs, identify skill gaps, and benchmark performance across cohorts. The platform also supports video-based morbidity and mortality case review, with annotation tools and secure cloud storage. If implemented well, this could replace ad-hoc video workflows that currently rely on consumer screen recorders, personal Dropbox accounts, and manual tagging, all of which introduce HIPAA risk.

The dual-use model is strategically clever. A residency program that already has 40 residents using the free app faces lower adoption friction when piloting the enterprise video tier. The UI is familiar, the login infrastructure is already in place, and the value proposition builds on existing user behavior rather than requiring greenfield training. This is rare in surgical tech, where most tools are either purely individual or purely institutional with no crossover.

Where it falls short

The enterprise tier's pricing is entirely opaque. Medtronic does not publish per-seat costs, per-procedure video storage fees, or implementation charges. Comparable platforms like Theator and ExplORer Surgical also operate on custom quotes, but industry chatter suggests annual contracts in the USD 50,000 to USD 200,000 range for mid-sized surgical programs. Without public benchmarks, buyers have no negotiating leverage and no ability to budget before engaging a sales cycle. This is a major friction point for academic medical centers operating under constrained capital budgets.

The evidence base is thin to the point of being nearly absent. The single PubMed citation we identified, a 2024 Surgical Endoscopy article on video management barriers, discusses the general category but does not evaluate Touch Surgery's platform. There are no published trials comparing Touch Surgery's simulator to control groups, no outcomes data linking app usage to operative performance, and no institutional case studies in peer-reviewed journals. For a tool targeting evidence-driven surgical programs, this is a red flag. Buyers are being asked to trust vendor claims without independent validation.

EHR integration depth is unclear. The platform's marketing materials do not specify whether the enterprise tier integrates bidirectionally with Epic, Cerner, or other major EHR systems. Can case logs auto-populate from the video analytics module into ACGME case log requirements? Can video timestamps sync with operative note timings? These workflow integrations are table stakes for institutional adoption, but Medtronic's public documentation does not address them. IT teams will need to interrogate this during vendor demos.

The mobile simulator, while free, is limited to cognitive rehearsal. It does not offer haptic feedback, does not require physical instrument manipulation, and cannot assess fine motor skills like suturing or knot-tying. For advanced learners seeking high-fidelity simulation, platforms like Osso VR or robotic surgery simulators from Intuitive Surgical offer more immersive training. Touch Surgery is best for early cognitive scaffolding, not for refinement of technical execution. Program directors should not expect this tool to replace hands-on simulation labs or cadaveric training.

Deployment realities

The free mobile app requires zero IT involvement. A medical student or resident downloads it from the App Store or Google Play, creates an account with an email address, and begins training immediately. There is no institutional contract, no MDM enrollment, no firewall exceptions, and no helpdesk tickets. For individual learners, deployment friction is effectively zero. This is a massive advantage over enterprise-only platforms that require institutional procurement cycles before any hands-on evaluation.

The enterprise tier, by contrast, likely requires multi-month deployment. Based on patterns from comparable surgical video platforms, expect a 90- to 180-day onboarding timeline that includes vendor scoping calls, IT security reviews, EHR integration discussions, OR camera installation or configuration, cloud storage provisioning, and end-user training for surgical faculty and residents. Medtronic does not publish implementation timelines, but surgical video platforms are infrastructure-heavy. Buyers should budget for at least one dedicated IT FTE during the deployment phase and ongoing fractional support thereafter.

Change management is non-trivial. Convincing attending surgeons to record cases, review footage, and adopt structured feedback workflows requires cultural buy-in, not just technical readiness. Surgical video analytics platforms succeed when championed by respected faculty leaders and integrated into existing morbidity-and-mortality conferences or competency committees. Without that organizational alignment, the platform risks becoming shelfware. Medtronic's sales materials emphasize this, but they do not provide turnkey change-management playbooks. Program directors should plan for internal evangelism and pilot cohorts before full rollout.

Pricing realities

The free app costs USD 0 per month and USD 0 per year, with no in-app purchases, no freemium upsells, and no usage caps. This is genuinely free, not a lead-generation funnel. Medtronic appears to treat the app as a long-term brand-building investment and a pipeline for eventual enterprise conversions. For individual clinicians, there are no hidden costs. Download it, use it indefinitely, and walk away if it does not fit your workflow.

The enterprise tier operates on a custom-quote model, meaning no public pricing benchmarks exist. Based on comparable platforms, expect annual contracts starting in the low five figures for small surgical programs (under 20 active users) and scaling into six figures for large academic medical centers with hundreds of surgical residents and faculty. Hidden costs likely include per-video storage fees (cloud hosting for surgical video is expensive), per-API-call charges if the platform integrates with third-party EHR or PACS systems, and professional services fees for onboarding, training, and custom workflow configuration. Medtronic sales teams will frame these as negotiable, but buyers should assume they are standard line items.

Contract terms are likely annual with auto-renewal clauses. Enterprise software in the medical device space typically locks buyers into 12-month commitments with 90-day opt-out windows. Early termination fees may apply if a program wants to exit mid-contract. Buyers should also scrutinize data ownership clauses. If your institution records 500 surgical videos and then cancels the contract, can you export that footage in a portable format, or does it remain in Medtronic's cloud indefinitely? These details are rarely advertised but are critical for long-term vendor independence. Negotiate data portability and export rights before signing.

Compliance + integration depth

Medtronic is a publicly traded Fortune 500 company with mature compliance infrastructure. The enterprise tier almost certainly holds HIPAA, SOC 2 Type II, and HITRUST certifications, though Medtronic's public documentation does not explicitly list these for the Touch Surgery product line. Buyers should request attestation letters and third-party audit reports during vendor diligence. Given Medtronic's regulatory footprint, expect these certifications to be available on request, but do not assume they are automatically included in standard contracts. Verify explicitly.

FDA clearance status is ambiguous. The mobile simulator is a training tool, not a diagnostic or therapeutic device, so it likely falls outside FDA regulatory scope as a Class I exempt educational software. The enterprise video analytics tier, if it makes any clinical decision-support claims (for example, flagging procedural deviations or risk-scoring techniques), could trigger FDA oversight as a Software as a Medical Device. Medtronic has not publicly stated whether Touch Surgery Enterprise has pursued FDA clearance. Buyers should ask directly, especially if they plan to use video analytics data for credentialing or privileging decisions, which could expose the institution to liability if the tool is not FDA-cleared.

EHR integration specifics are not documented in public materials. Medtronic's website does not name Epic, Cerner, Meditech, or other EHR vendors as certified integration partners. This is a significant gap. For the enterprise tier to deliver ROI, it must auto-populate case logs into ACGME-compliant formats, sync video metadata with operative notes, and ideally push competency milestones into GME management systems. Without named integrations, buyers should assume manual data transfer and plan for administrative overhead. During vendor demos, insist on seeing live EHR integration workflows, not just screenshots or roadmap promises.

Vendor stability + roadmap

Medtronic acquired Touch Surgery in 2020 for an undisclosed sum and rebranded it as Medtronic Digital Surgery. This acquisition brought the platform under the umbrella of a USD 30 billion medical device giant with over 90,000 employees, global regulatory reach, and deep relationships with hospital systems worldwide. From a vendor-stability perspective, this is as low-risk as it gets in health tech. Medtronic is not going to pivot away from surgical innovation, run out of runway funding, or get acquihired by a competitor. The platform will continue to exist and receive updates.

That said, large-company product roadmaps move slowly. Touch Surgery is a small piece of Medtronic's broader surgical portfolio, which includes robotic surgery systems, energy devices, and imaging platforms. It is unlikely to receive the rapid iteration cycles typical of venture-backed startups. Expect conservative feature releases, long QA cycles, and prioritization aligned with Medtronic's enterprise sales strategy rather than user-driven feature requests. For buyers who want bleeding-edge AI features or rapid customization, this corporate pace may feel sluggish.

Publicly stated roadmap details are sparse. Medtronic's investor materials and press releases emphasize surgical robotics and AI-assisted procedural guidance as long-term focus areas, but they do not break out Touch Surgery's specific development pipeline. Likely future directions include expanded specialty coverage in the mobile app, deeper AI tagging in the enterprise video tier, and potential integration with Medtronic's Hugo robotic surgery platform for automated video capture during robotic cases. None of this is confirmed, but it aligns with the company's stated digital surgery strategy. Buyers should ask for a product roadmap presentation during vendor diligence and request quarterly update cadences post-contract.

How it compares

Against Osso VR, Touch Surgery loses on immersive realism but wins on accessibility. Osso VR offers full VR headset-based simulation with haptic controllers, spatial anatomy, and team-based OR scenarios. It is the gold standard for high-fidelity surgical rehearsal. But it requires Meta Quest headsets, dedicated physical space, and per-seat annual licenses starting around USD 2,000 per learner. Touch Surgery's free mobile app delivers cognitive rehearsal with zero hardware requirements and zero cost. For early learners building procedural mental models, Touch Surgery is the better on-ramp. For advanced learners refining technical skills, Osso VR is worth the investment.

Against Theator, Touch Surgery is less mature in the video analytics space but potentially more integrated if you already use the free app. Theator is a pure-play surgical video intelligence platform with FDA clearance for certain AI-assisted annotations. It offers deeper analytics, more granular procedural tagging, and stronger published evidence, including peer-reviewed case studies and partnerships with major academic centers. Touch Surgery's enterprise tier, by comparison, is newer, less proven, and less transparent in its AI methodology. If your primary goal is video-based quality improvement, Theator is the safer bet. If you want a bundled simulator-plus-video solution with Medtronic backing, Touch Surgery may justify the trade-off.

Against ExplORer Surgical from Johnson & Johnson, Touch Surgery faces similar challenges. ExplORer is another established surgical video platform with strong OR integration, AI-powered procedural tagging, and published institutional case studies. J&J's device ecosystem also provides natural integration points for video capture in laparoscopic and robotic cases. Touch Surgery does not appear to have equivalent device-level integrations yet. The differentiator remains the free mobile app. If your institution values resident self-directed learning as much as faculty-driven video review, Touch Surgery's dual-mode model is more versatile. If video analytics alone is the priority, ExplORer and Theator are more feature-complete.

Against PrecisionOS, another VR-based orthopedic surgery simulator, Touch Surgery again wins on cost and accessibility but loses on realism. PrecisionOS offers highly detailed VR modules for joint replacement, trauma surgery, and spine procedures, with haptic feedback and anatomy validated by orthopedic surgeons. It is expensive and hardware-dependent. Touch Surgery's orthopedic modules are cognitive walkthroughs, not hands-on simulators. For orthopedic residency programs with VR budgets, PrecisionOS is the better training tool. For individual orthopedic residents seeking free procedural review, Touch Surgery is the pragmatic choice.

What clinicians say

We found zero Reddit mentions of Touch Surgery Enterprise across r/medicine, r/Residency, r/surgery, and related clinical subreddits. This absence is notable. Most widely adopted surgical tools, whether positive or negative, generate at least anecdotal user discussion in online clinician communities. The lack of chatter suggests either limited real-world penetration outside Medtronic's direct sales channels or a user base that skews younger and less engaged in Reddit-based professional communities.

The silence is not inherently negative, but it is a red flag for evidence-seeking buyers. When clinicians love a tool or hate a tool, they talk about it. When a tool generates no discussion, it may mean adoption is still early-stage, the user experience is unmemorable, or the platform is used passively without strong engagement. For the free mobile app, this is less concerning, since individual learners may download it, use it sporadically, and never think to discuss it online. For the enterprise tier, the absence of institutional testimonials or user-generated case studies is harder to explain. Buyers should ask Medtronic for customer references and insist on speaking with peer institutions before committing.

Without clinician testimonials, we cannot validate vendor claims about usability, workflow fit, or ROI. This is a blind spot. Proceed cautiously and plan for a pilot deployment with structured feedback collection before scaling across a full surgical program.

What the literature says

We identified one PubMed citation tangentially related to surgical video analytics: a 2024 article in Surgical Endoscopy titled "Current trends and barriers to video management and analytics as a tool for surgeon skilling." The study discusses general challenges in implementing video-based surgical training programs, including technical barriers, workflow integration friction, and cultural resistance from attending surgeons. It does not evaluate Touch Surgery specifically, nor does it provide comparative effectiveness data. The article is useful for understanding the broader category's pain points but offers no evidence for or against this particular platform.

We found no prospective trials, no randomized controlled studies, no before-and-after case reports, and no institutional outcomes papers evaluating Touch Surgery's mobile simulator or enterprise video tier. For a platform that has existed in some form since 2013 (pre-Medtronic acquisition) and that targets academic medical centers, this evidence gap is striking. Comparable tools like Osso VR and FundamentalVR have published validation studies showing skill transfer from simulation to live OR performance. Touch Surgery does not.

This lack of published evidence does not prove the tool is ineffective, but it does mean buyers are operating on vendor claims alone. For CMIO-led procurement decisions that require evidence-based justification to finance committees or surgical department chairs, this is a major limitation. If you proceed with enterprise deployment, plan to collect your own outcomes data and consider publishing it. The field needs more independent evaluation, and your institution's experience could fill that gap.

Who it's for

The free mobile app is for surgical residents, medical students, and early-career surgeons across all specialties. If you want low-friction cognitive rehearsal for procedural steps, anatomical landmarks, and decision trees, download it today. There is no financial risk, no institutional approval required, and no training overhead. Use it as a study aid before scrubbing in, as a review tool after observing cases, or as a self-assessment platform during exam prep. This is especially valuable for learners in under-resourced programs with limited simulation lab access or for international medical graduates preparing for U.S. residency.

The enterprise tier is for surgical program directors at academic medical centers, large community hospital surgical programs, and integrated delivery networks exploring video-based quality improvement. If you already have institutional buy-in for video capture, if your faculty are culturally open to recorded case review, and if you have IT resources to support a multi-month deployment, Touch Surgery's enterprise tier is worth a pilot. Start with a small cohort, one or two surgical subspecialties, and a defined six-month evaluation period. Measure adoption rates, workflow friction, and any measurable improvements in case log accuracy or competency milestone tracking. If the pilot delivers ROI, scale. If it does not, the contract terms will let you exit.

Skip the enterprise tier if your institution lacks video-capture infrastructure, if your surgical faculty are skeptical of recorded review, or if you need immediate EHR integration and transparent pricing. The evidence base is too thin and the pricing too opaque for high-conviction enterprise buys. Wait for more published case studies, clearer integration roadmaps, and competitive pressure that forces Medtronic to disclose pricing benchmarks. For now, the free app is a clear win. The enterprise tier is a cautious maybe.

The verdict

Touch Surgery Enterprise is two products masquerading as one. The free mobile simulator is an unambiguous win: high-quality procedural training content, zero cost, zero friction, and Medtronic-backed stability. Every surgical trainee should download it. The enterprise video tier is murkier: opaque pricing, thin evidence, unclear EHR integration, and no independent validation. It may deliver value for surgical programs with strong internal champions and tolerance for vendor risk, but it is not a safe default buy.

If you are a surgical resident or medical student, download the free app immediately. It costs nothing, requires no institutional approval, and delivers legitimate educational value. If you are a program director considering the enterprise tier, insist on a pilot with clear success metrics, negotiate data portability clauses, and demand customer references from peer institutions. Do not sign a multi-year contract based on vendor promises alone. The evidence gap is too wide. If you are a CMIO evaluating surgical video platforms broadly, compare Touch Surgery's enterprise tier against Theator, ExplORer Surgical, and other category leaders. Touch Surgery's free app gives it a unique bundled advantage, but that alone does not justify weaker analytics or higher vendor lock-in risk.

Final scoring: the free app earns a strong recommendation for individual learners. The enterprise tier earns a conditional recommendation for institutions willing to pilot cautiously. Overall, this is a platform to watch, not yet a platform to bet on at enterprise scale. If Medtronic publishes outcomes data, clarifies EHR integrations, and discloses pricing benchmarks, that calculus will shift. Until then, proceed with eyes open and exit clauses negotiated.